Curriculum Vitae:
David Sert Krakow, M.D.

EDUCATION

1979 – 1983 BA, Connecticut College, New London, CT
1985 – 1986 Harvard University, Cambridge, MA
Post–baccalaureate Pre-medical Program
1985 – 1987 Wellesley College, Wellesley, MA
Post–baccalaureate Pre-medical Program
1987 – 1991 M.D., Hahnemann University School of Medicine, Philadelphia, PA
Major in Economics, Minor in English Literature

POSTDOCTORAL TRAINING

July 1991 – June 1992 Intern, Departments of Medicine and Psychiatry (PGY I), New York University Medical Center, New York, NY
July 1992 – June 1995 Resident, General Psychiatry (PGY II-IV), New York University Medical Center, New York, NY
July 1994 – June 1995 Chief Resident, Department of Psychiatry (PGY IV), New York University Medical Center, New York, NY
February 1995 – February 1996 Psychoanalytic Psychotherapy Fellow, Columbia University Psychoanalytic Institute; Director, Don Meyers, M.D.
Columbia University and Medical Center, College of Physicians and Surgeons, New York, NY
July 1, 1995 – June 30, 1997 Research and Clinical Addiction Medicine Fellow; Director, Marc Galanter, M.D. Department of Psychiatry, New York University Medical Center, New York, NY

LICENSURES

1992 – Present State of New York, Medical and Surgical License
1993 – Present New York State Department of Health, Bureau of Controlled Substances

SPECIALTY CERTIFICATIONS

1996 Certified by the American Board of Psychiatry and Neurology in Psychiatry, Number 42498
1998 Certified by the American Board of Psychiatry and Neurology for subspecialty certification in Addiction Psychiatry
2006 Recertified by the American Board of Psychiatry and Neurology in Psychiatry, Number 42498

ACADEMIC APPOINTMENTS

July 1994 – June 1997 Clinical Instructor in Psychiatry, New York University Medical Center, New York, NY
July 1997 – June 1998 Assistant Professor of Psychiatry, Albert Einstein College of Medicine, New York, NY
November 1998 – June 2002 Adjunct Assistant Professor of Psychiatry and Behavioral Sciences, New York Medical College, New York, NY
July 1, 1998 – Present Assistant Clinical Professor of Psychiatry, College of Physicians & Surgeons of Columbia University, New York, NY

PRIVATE PRACTICE

July 1995 – Present Solo Private Practice in Psychopharmacology, Addiction Medicine and Psychodynamic Psychotherapy

RESEARCH PRACTICE

August 2002 – Present Director of Bioscience Research, LLC

HOSPITAL AND CLINICAL APPOINTMENTS

July 1991 – June 1992 Intern, Department of Psychiatry and Department of Medicine, New York University Medical Center, New York, NY
July 1992 – June 1995 Resident, Department of Psychiatry, New York University Medical Center, New York, NY
July 1994 – June 1995 Chief Resident, Department of Psychiatry, New York University Medical Center, New York, NY
July 1995 – June 1997 Attending Psychiatrist, Bellevue Hospital and Medical Center, New York, NY
July 1995 – June 1997 Attending Psychiatrist, New York University Medical Center, New York, NY
July 1995 – 1996 Medical Director, Cocaine Clinic, Bellevue Hospital and the New York University Medical Center, New York, NY
November 1997 – Present Official Evaluation and Treatment Provider for the Office of Professional Medical Conduct of the New York State Department of Health
July 1997 – December 1998 Attending Psychiatrist, Department of Psychiatry, Beth Israel Medical Center, New York, NY
November 1997 – Present Official Evaluation and Treatment Provider for the Committee for Physicians' Health of the Medical Society of the State of New York
July 1997 – December 1998 Medical Director and Chief Psychiatrist, National Institute on Drug Abuse Grant # 5R01DA09583-02, "Imipramine and Relapse Prevention in Depressed Methadone Patients", Psychiatric Institute, Columbia University and Medical Center, College of Physicians and Surgeons, New York, NY
January 1999 – Sept. 1999 Medical Director, Alcohol and Parole Treatment Programs, Greenwich House, New York, NY
October 1999 – June 2002 Attending Physician; Research Consultant, Department of Psychiatry, Saint Vincent’s Hospital and Medical Center, New York, NY
August 1, 2000 – Present Medical Staff of the Department of Psychiatry and Behavioral Sciences at Saint Vincent’s Hospital and Medical Center

TEACHING EXPERIENCE

1993 – 1994 Supervision given to third and fourth year medical students in the Bellevue Hospital Comprehensive Psychiatric Evaluation Program
1995 – 1997 "Network Therapy"; Thirteen week course given to third year General Psychiatry Residents at the New York University Medical Center, New York, NY
1995 – 1997 "Addiction Medicine Course"; Physician in charge of coordinating and teaching third and fourth year medical students, New York University Medical Center, New York, NY
1995 – 1997 Individual Weekly Psychopharmacological and Psychodynamic Psychotherapy supervision to third and fourth year General Psychiatry Residents at the New York University Medical Center, New York, NY
1994 – 1997 "Psychiatric Clinical Clerkships"; preceptor to third and fourth year medical students, New York University Medical Center, New York, NY
March 1996 "The Neurobiology of Addictive Illnesses"; Lecture series given to second year medical students, New York University School of Medicine, New York University Medical Center, New York, NY
August 1996 "Neurobiology: how it has contributed to our understanding of Opiate Addiction"; Lecture given to third and fourth year medical students, New York University Medical Center, New York, NY
September 1996 "Ethanol and the Central Nervous System"; Lecture given to third and fourth year medical students, New York University Medical Center, New York, NY
October 1996 "Heroin: The New Crisis?" Lecture given to third and fourth year medical students, New York University Medical Center, New York, NY
December 1996 "Different Treatment Approaches to Alcoholism"; Lecture given to third and fourth year medical students, New York University Medical Center, New York, NY
January 1997 "Medical Complications of Alcoholism"; Lecture given to third and fourth year medical students
February 1997 "Heroin: Epidemiology, Pharmacology and Treatment"; Lecture given to third and fourth year medical students, New York University Medical Center, New York, NY , New York University Medical Center, New York, NY
April 1997 "The Neurobiology of Cocaine Addiction”; Lecture given to third and fourth year medical students, New York University Medical Center, New York, NY
May 1997 “Cocaine: Therapeutic communities"; Lecture given to third and fourth year medical students, New York University Medical Center, New York, NY
June 1997 "Cocaine: Epidemiology, Pharmacology and Treatment"; Lecture given to third and fourth year medical students, New York University Medical Center, New York, NY
July 1997 – Dec. 1998 "Journal Club"; a weekly seminar that I present to the staff of the “Imipramine and Relapse Prevention in Depressed Methadone Patients” research project
January 1998 "The Neurochemistry and Molecular Biology of Antidepressant Medications"; Course given to first and second year Child and Adolescent Psychiatry Fellows, St. Vincent’s Hospital and Medical Center, New York, NY
September 1998 – Present "Psychiatric Medicine I and Psychiatric Medicine II" a yearlong course taught to the first and second year Medical students at the College of Physicians and Surgeons of Columbia University, New York, NY

RESEARCH ACTIVITIES 1995-1997

1. Imipramine and Relapse Prevention in Depressed Methadone Patients. Co-Investigator: David Sert Krakow, M.D.
2. HIV Risk Factors in Dually Diagnosed Patients. Principal Investigator: David Sert Krakow, M.D.
3. Tuberculosis in Dually Diagnosed Patients. Principal Investigator: Tania Taubes M.D. Co-Investigator: David Sert Krakow, M.D.
4. Predictors of Treatment Outcome in Dually Diagnosed Patients. Principal Investigator: Daniel Leal, M.D. Co-Investigator: David Sert Krakow, M.D.
5. Buprenorphine in Detoxification of Opiate Addicts. Principal Investigator: William Matikiewitz, M.D.
6. Network Therapy for the Office Practitioner. Principal Investigator: Marc Galanter, M.D.
7. Cigarette Smoking Patterns in Dually Diagnosed Patients. Principal Investigator: Steven Taylor, M.D.
8. Predictors of Retention in a Modified Therapeutic Community. Principal Investigator: Daniel Mierlak, M.D.

RESEARCH STUDIES CONDUCTED

1. Population Pharmacokinetic Study in Adolescent Patients with Schizophrenia or Bipolar I Disorder Treated with Olanzapine. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Eli Lilly & Company, February 2000.
2. The Study of Olanzapine plus Fluoxetine in Combination for Treatment-resistant Depression Without Psychotic Features. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lilly & Company, February 2000.
3. Olanzapine vs. Placebo in the Treatment of Adolescents with Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lilly & Company, February 2000.
4. Olanzapine vs. Placebo in the Treatment of Mania in Adolescents with Bipolar I Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lilly & Company, February 2001.
5. A Phase III, Randomized, Multi-center, Double-blind, Parallel-group, Placebo-controlled Safety and Efficacy Study of ADDERALL XR® with an Open-label Extension, in the Treatment of Adolescents Aged 13–17 with Attention Deficit Hyperactivity Disorder (ADHD). Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., February 2001.
6. A comparison of fasting triglyceride levels cohorts with schizophrenic and related disorder treated chronically with Olanzapine, Risperidone and typical anti-psychotics. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lily & Company; August 2001.
7. Olanzapine vs. Ziprasidone in the treatment of Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lily & Company; August 2001.
8. Olanzapine vs. Risperidone in the treatment of Bipolar I disorder, mixed or manic. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lily & Company; August 2001.
9. The Efficacy and Safety of Risperidone in the treatment of Children and Adolescents with Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D.; Sponsor: Janssen/Medex; April 2001.
10. A Multi-center, Randomized, Double-blind Study and Tolerability Study of Flexible Doses of Aripiprazole and Olanzapine in the Treatment of Patients with Acute Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Bristol Myers Squibb; October 2000.
11. A Multi-center, Randomized, Double-blind Study of Flexible Doses of Aripiprazole vs. Perphenazine in the Treatment of Patients with Treatment-Resistant Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Bristol Myers Squibb; August 2000.
12. Olanzapine Plus Fluoxetine Combination Therapy in Treatment Resistant Depression: A Dosing Range Study: Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.: Sponsor: Eli Lilly and Co.; March 2000.
13. A Double-blind, 12-Month Continuation Protocol for Patients who Successfully Completed Protocol RO548. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Pfizer/Scirex; April 2000.
14. A Double-blind Multi-center Study Comparing The Safety and Efficacy of Ziprasidone to Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Pfizer/Scirex; April 2000.
15. A Multi-center, 10-Week, Randomized, Double-blind Study of Sertraline and Placebo in Children and Adolescents with Post-traumatic Stress Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Pfizer Pharmaceuticals Group; January 2003.
16. A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults with Attention-Defecit/Hyperactivity Disorder: with a Secondary Examination of Impact of Treatment on Family Functioning. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Eli Lilly & Company; 2004.
17. A Multi-center, Open-label Safety and Tolerability Study of Flexible-Dose Oral Aripiprazole (2mg – 30mg) in the Treatment of Adolescent Patients with Schizophrenia, and Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Otsuka Maryland Research Institute, Inc., February 2005.
18. A Multi-center, Randomized, Double-blind, Placebo-controlled Study with Two Fixed Oral Doses of Aripiprazole (10mg or 30mg) in the Treatment of Adolescent Patients with Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Otsuka Maryland Research Institute, Inc., 2005.
19. A Multi-center, Randomized, Double-blind, Placebo-controlled Study of Two Fixed Oral Doses of Aripiprazole (10mg or 30mg) in the Treatment of Child and Adolescent Patients Aged 10–17 Years, with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Otsuka Maryland Research Institute, Inc., February 2005.
20. A Randomized, Multicenter, Double-Blind, Parallel Group Study to Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenia Patients. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Solvay Pharmaceuticals; January 2007.
21. A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of BMS-562086 in the Treatment of Outpatients with Major Depressive Disorder. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Bristol-Myers Squibb Pharmaceutical Research Institute; March 2007.
22. A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of Pexacerfont (BMS-562086) in the Treatment of Outpatients with Generalized Anxiety Disorder. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Bristol-Myers Squibb Pharmaceutical Research Institute; July 2007.
23. An Open-Label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in the Treatment of Children and Adolescents with Major Depressive Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lilly and Company; August 2007.
24. A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients with Major Depression Disorder. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: PGx Health; January 2008.
25. A Phase III, Open-label Study of SPD503 in Children and Adolescents aged 6–17 with Attention Deficit Hyperactivity Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., February 2008.
26. A Phase III, Randomized, Multi-center, Double-blind, Parallel-group, Placebo-controlled Safety and Efficacy Study of SPD503 in Children and Adolescents aged 6–17 with Attention Deficit Hyperactivity Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., February 2008.
27. A 12 Week, Randomized, Open-Label Trial of Duloxetine Versus Generic SSRIs in the Treatment of a Severe Depressive Episode. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Eli Lilly, May 2008.
28. The Evaluation of LAMICTAL™ as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age. Principal Investigator: Jeanette Cueva, M.D., Co-Investigator: David Krakow, M.D.; Sponsor: GlazoSmithKline, July 2008.
29. A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination With Psychostimulants in Children and Adolescents Aged 6-17 With a Diagnosis of ADHD. Principal Investigator: Jeanette Cueva, M.D., Co-Investigator: David Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., September 2008.
30. A Phase III, Open-Label, Extension, Multi-center, Safety and Efficacy Study of LDX in Adolescents Aged 13-17 with ADHD. Principal Investigator: Jeanette Cueva, M.D., Co-Investigator: David Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., October 2008.
31. A Phase III, Randomized, Double-Blind, Multi-center, Parallel-Group, Placebo-Controlled, Forced-Dose Titration, Safety and Efficacy Study of LDX in Adolescents Aged 13-17 With ADHD. Principal Investigator: Jeanette Cueva, M.D., Co-Investigator: David Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., October 2008.
32. A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Efficacy and Safety Study of AZDXXXX in the Treatment of Generalized Anxiety Disorder (GAD). Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: AstraZeneca, February 2009.
33. A Multicenter, Long-Term, Open-Label Study to Assess the Safety and Tolerability of OPC-XXX as Adjunctive Therapy in the Treatment of Outpatients with Major Depressive Disorder. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc., May 2009.
34. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of OPC-XXX as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc., May 2009.
35. A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study of 3 Dosages of JNJ-XXX in the Treatment of Adult Subjects with Attention-Deficit/Hyperactivity Disorder. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Johnson & Johnson Pharmaceutical Development & Commercialization, Inc., May 2009.
36. A Double-blind, placebo-controlled study of Cariprazine as adjunctive therapy in Major Depressive Disorder. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Forest Laboratories, July 2009.
37. A Study to Assess the Long-Term Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Fluoxetine Only in the Relapse Prevention of Stabilized Patients with Treatment-Resistant Depression. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Eli Lilly, August 2009.
38. A 12 week, randomized, double-blind, placebo-controlled, phase III safety trial of XXX tablets (100 milligrams daily) in women taking a selective serotonin or serotonin –norepinephrine reuptake inhibitor with decreased sexual desire and distress. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Boehringer-Ingelheim Pharmaceuticals, March 2010.
39. A Phase 4, randomized, double-blind, multicenter, placebo-controlled, parallel group study evaluating the safety and efficacy of XXX on executive function (self-regulation) behaviors in adults with ADHD reporting clinically significant impairment of real-world executive function behavior. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., April 2010.
40. A Phase III, Placebo-controlled, Long-Term Safety and Tolerability Study of TC-5214 as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: AstraZeneca, September 2010.
41. A Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to SSRI Treatment. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Eli Lilly & Company, October 2010.
42. A Phase III, Placebo-controlled, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: AstraZeneca, January 2011.
43. A Phase IIIb, randomized, double blind, placebo-controlled, 13-week clinical trial to assess the efficacy and safety of Duloxetine 30/60 mg QD compared to placebo in adolescents with Juvenile Primary Fibromyalgia Syndrome. Continued efficacy and safety of Duloxetine 30/60 mg QD will be assessed in a 26-week, open-label treatment extension period. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Eli Lilly, May 2011.
44. A Multicenter, Randomized, Double-Blind, Active-Controlled, Comparative Fixed-Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depression. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Bristol Meyers Squibb, June 2011.
45. A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Bristol Meyers Squibb, June 2011.
46. A Multicenter, Randomized, Double-Blind, Placebo controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Children and Adolescent Outpatients with Major Depression a Placebo-Controlled, Comparative Fixed-Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depression. Principal Investigator: Jeanette E. Cueva, M.D. Co- Investigator: David Sert Krakow, M.D.,; Sponsor: Pfizer, June 2011.

HONORS AND AWARDS

1987 Hahnemann University School of Medicine, Department of Psychiatry, Letter of Commendation in Psychopathology 1987 Hahnemann University School of Medicine, Department of Psychiatry, Letter of Commendation in Associated Psychiatry Program
1988 Hahnemann University School of Medicine, Department of Psychiatry. Fellowship and stipend awarded for the study of Alcohol, Cocaine and Heroin substance abuse in the department of Psychiatry, University of Pennsylvania, Philadelphia, PA
1988 Hahnemann University School of Medicine, Department of Psychiatry, Letter of Commendation in Introduction to Psychotherapy and Advanced Diagnostics
1988 Hahnemann University School of Medicine, Department of Psychiatry, Letter of Commendation in Accelerated Psychiatry Program
1990 New York University School of Medicine, Department of Psychiatry, Letter of Commendation in Psychiatry Sub-internship
1990 Hahnemann University School of Medicine, Department of Neurology, Letter of Commendation in Senior Neurology Rotations
2009 Nancy C.A. Roeske, M.D., Certificate of Excellence presented at The 161st Annual Meeting of the APA

MEMBERSHIP IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

1991 – Present American Psychiatric Association
1996 – Present American Academy of Addiction Psychiatry
1996 – Present American Society of Addiction Medicine
1998 – Present American Academy of Psychoanalysis
1998 – Present American College of Forensic Examiners

COMMITTEE APPOINTMENTS

July 1994 – June 1995 Third and Fourth Year Psychiatry Residents Steering Committee, New York University Medical Center, Department of Psychiatry, New York, NY
July 1994 – June 1995 Second Year Psychiatry Residents Steering Committee, New York University Medical Center, Department of Psychiatry, New York, NY
July 1994 – June 1995 Curriculum Committee, New York University Medical Center, Department of Psychiatry, New York, NY
July 1994 – June 1995 Steering Committee, New York University Medical Center, Department of Psychiatry, New York, NY

PUBLICATION IN JOURNALS

Krakow D, Galanter M, Dermatis H, Westreich L: HIV Risk Factors in Dually Diagnosed Patients, American Journal on Addiction, 1998; 7:74 – 80.

BOOK CHAPTERS

Krakow D: Competency and Other Legal Issues.
In: Bernstein C, Ladds B, Maloney A, Weiner E,
(Ed.), On Call Psychiatry. Philadelphia, W.B.Saunders Company, pp 27 – 33.

PRESENTATIONS AND LECTURES

March 1994 "Depression: Etiology, Diagnosis and Treatment". Presented at the Brystol-Myers-Squib Nefazadone National Launch, Dallas TX
November 1995 "Good Day America". Appeared on the TV show to give advice on marital relationships
June 1997 "Dually Diagnosed Patients in the Prison System: Evaluation and Treatment". Presented at the OASIS/OMH Conference on Persons with Co-Occurring Psychiatric and Substance Abuse Disorders in the Criminal Justice System, Albany, NY
February 1998 "Depression: What Do We Know?". Presented to the Department of Medicine, Beth Israel Medical Center, New York, NY
March 1998 "The Neurobiology of Addiction". Presented to the Department of Psychiatry, Grand Rounds, St. Vincent’s Hospital and Medical Center, New York, NY
April 1998 "The Signs and Symptoms of Depression" Presented at the Fifty Plus Expo, Madison Square Garden, New York, NY
June 1998 "Research Report from the APA: What’s new and Exciting." Dinner Symposium sponsored by Pfizer, New York, NY
September 1998 "The Neurobiology of Addictive Illnesses". Presented to the Department of Psychiatry, Grand Rounds, New York University Medical Center, New York, NY
November 1998 "The Neurobiology of Addiction". Presented to the Department of Psychiatry, Grand Rounds, New York Medical College, Valhalla, NY
March 1999 "Depression: Update on Treatment." Presented to the Department of Medicine, Grand Rounds, New York Downtown Hospital, New York, NY

WORKSHOPS ATTENDED AT COLUMBIA UNIVERSITY

1. Workshop on the Structured Clinical Interview for DSM-IV (SCID for DSM-IV) (by Susan Tross Ph.D.), Columbia University, New York, NY, July 8 – 10, 1997
2. Rater Assessment Training (Hamilton Depression Scale, Beck Depression Scale, Hamilton Anxiety Scale, Clinical Global Rating) (by Susan Tross Ph.D.), Columbia University, New York, NY, July 15 – 17, 1997
3. Workshop on the Addiction Severity Index and the Quantitative Substance Use Inventory (by Susan Tross Ph.D.), Columbia University, New York, NY, July 25, 1997
4. "An interdisciplinary Perspective on Substance Abuse education," The New York State Addiction Technology Transfer Center and New York University Medical Center, New York, June 10, 1998

WORKSHOP ATTENDED AT NEW YORK UNIVERSITY

Workshop on the Brief Psychiatric Rating Scale (BPRS) (by Marc Galanter, M.D.), November 4 – 6, 1997

OTHER WORKSHOPS ATTENDED

1. The Metapsychology of Dr. Davanloo’s Short Term Psychoanalytically Based Psychotherapy, February 24, 1993, Park City, Utah
2. Short-term Psychoanalytically Based Psychotherapy with Dr. Malan, November 14 – 16 1994, New York, NY
3. Short-term Psychoanalytically Based Psychotherapy with Dr. Davenloo, Harvard Medical School, June 16 – 21, 1994
4. Buprenorphine Training Session: Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence, sponsored by the American Academy of Addiction Psychiatry, January 18, 2002

NATIONAL MEETINGS ATTENDED

1. American Psychiatric Association, Annual Meeting, Washington D.C. May 2-7, 1992
2. Association for Research in Nervous and Mental Diseases, Annual Meeting, "Biology of Schizophrenia and Affective Disease", New York, NY, December 3-4, 1993
3. "Mood Disorders and their Effective Treatment", Harvard Medical School, Department of Continuing Education, Boston, MA, April 2-4, 1993
4. American Psychiatric Association, Annual Meeting, Philadelphia, PA May 21-27, 1994
5. New Clinical Drug Evaluation Unit Program/NCDEU, 34th Annual Meeting, Marco Island, FL, May 31-June 3, 1994
6. "Clinical Neurology for Psychiatrists" Albert Einstein College of Medicine, New York, NY, September 29-October 1, 1995
7. American Psychiatric Association, Annual Meeting, Miami, FL, May 20-25, 1995
8. "New Approaches to the Treatment of Alcoholism", Columbia University College of Physicians and Surgeons, New York, NY, June 21, 1995
9. American Psychiatric Association, Annual Meeting, New York, NY, May 4-9, 1996
10. American Psychiatric Association, Annual Meeting, San Diego, CA, May 17-22, 1997
11. "Psychopharmacology Annual Review", New York University Medical Center, New York, NY March 7, 1998
12. American Psychopathological Association, Annual Meeting, "Childhood Onset of Adult Psychopathology", New York, NY, March 5-7, 1998
13. Columbia University College of Physicians and Surgeons, Center for Continuing Education, "Gender and Depression: Perspectives for the new Millennium", New York, NY, April 30,1998-May 1, 1998
14. New York University Medical Center, The New York Addiction Transfer Center, "An Interdisciplinary Perspective in Substance Abuse Education", New York, NY, June 10, 1998
15. Association for Research in Nervous and Mental Diseases, Annual Meeting, "The Neurobiology of Psychiatry", New York, NY, December 4-5, 1998
16. American Psychiatric Association, Annual Meeting, Washington, DC, May 15-20, 1999
17. American Psychiatric Association, Annual Meeting, Chicago, IL, May 13-18, 2000
18. American Psychiatric Association, Annual Meeting, New Orleans, LA, May 5-10, 2001
19. American Psychiatric Association, Annual Meeting, Philadelphia, PA, May 18-23, 2002.
20. American Psychiatric Association, Annual Meeting, San Francisco, CA, May 17-22, 2003
21. American Psychiatric Association, Annual Meeting, New York, NY, May 1-6, 2004
22. American Psychiatric Association, Annual Meeting, Atlanta, GA, May 21-26, 2005
23. American Psychiatric Association, Annual Meeting, Toronto, Canada, May 20-25, 2006

INTERNATIONAL MEETINGS ATTENDED

1. First International Congress on Hormones, Brain and Neuropsychopharmacology, Rhodes, Greece, September 13 – 17, 1993.
2. Health Care Delivery System in France, Louis Pasteur Institute, Paris, France, May 4 – 8, 1998.

top